XML 12 R2.htm IDEA: XBRL DOCUMENT v3.8.0.1
Condensed Consolidated Balance Sheets - USD ($)
$ in Millions
Dec. 31, 2017
Jun. 30, 2017
Current assets:    
Cash and cash equivalents $ 88.7 $ 102.4
Marketable investment securities 54.8 48.3
Prepaid expenses 9.8 12.7
Inventory 38.2 42.2
Trade accounts receivable, less allowance for doubtful accounts of $9.5 December 31, 2017 and $8.2 June 30, 2017 121.1 105.6
Prepaid taxes 8.4 0.2
Other receivables 6.0 5.7
Total current assets 327.0 317.1
Property, plant and equipment, net 48.4 51.1
Long-term marketable investment securities 58.5 48.5
Intangibles, net 475.2 491.6
Goodwill 319.4 316.1
Total assets 1,228.5 1,224.4
Current liabilities:    
Accounts payable 25.1 22.0
Accrued liabilities 60.8 65.6
Short-term contingent consideration 70.0 127.3
Deferred revenue 3.4 2.6
Total current liabilities 159.3 217.5
Unrecognized tax benefits 33.4 25.2
Other long-term liabilities 6.6 7.2
Contingent consideration 11.0 13.2
Long-term debt 43.2 99.1
Long-term deferred taxes 60.8 84.4
Total liabilities 314.3 446.6
Commitments and contingencies
Stockholders’ equity:    
Common stock, 69.4 and 68.4 shares outstanding at December 31, 2017 and June 30, 2017 respectively 0.7 0.7
Additional paid-in capital 871.1 851.4
Accumulated other comprehensive loss (2.4) (5.5)
Retained earnings (deficit) 44.8 (68.4)
Total Myriad Genetics, Inc. stockholders’ equity 914.2 778.2
Non-Controlling Interest   (0.4)
Total stockholders' equity 914.2 777.8
Total liabilities and stockholders’ equity $ 1,228.5 $ 1,224.4